S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Is There Still Time to Get In On the Lithium Boom? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Is There Still Time to Get In On the Lithium Boom? (Ad)
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
SunCar Technology Stock Overheats...Will it Rise Again?
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Is There Still Time to Get In On the Lithium Boom? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Is There Still Time to Get In On the Lithium Boom? (Ad)
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
SunCar Technology Stock Overheats...Will it Rise Again?
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Is There Still Time to Get In On the Lithium Boom? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Is There Still Time to Get In On the Lithium Boom? (Ad)
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
SunCar Technology Stock Overheats...Will it Rise Again?
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Is There Still Time to Get In On the Lithium Boom? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Is There Still Time to Get In On the Lithium Boom? (Ad)
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
SunCar Technology Stock Overheats...Will it Rise Again?
TSE:HLS

HLS Therapeutics (HLS) Stock Forecast, Price & News

C$4.30
0.00 (0.00%)
(As of 06/5/2023 ET)
Compare
Today's Range
C$4.29
C$4.30
50-Day Range
C$4.15
C$6.45
52-Week Range
C$4.12
C$14.86
Volume
4,100 shs
Average Volume
22,258 shs
Market Capitalization
C$139.11 million
P/E Ratio
N/A
Dividend Yield
4.65%
Price Target
C$24.25

HLS Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
360.5% Upside
C$19.80 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
C$11,250 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars


HLS stock logo

About HLS Therapeutics (TSE:HLS) Stock

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.

Receive HLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HLS Stock News Headlines

ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
HLS Therapeutics Inc (HLS) Receives a Buy from Stifel Nicolaus
Closing Bell: Hls Therapeutics Inc up on Thursday (HLS)
ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
Closing Bell: Hls Therapeutics Inc down on Friday (HLS)
Closing Bell: Hls Therapeutics Inc flat on Thursday (HLS)
HLS Therapeutics appoints CEO
Closing Bell: Hls Therapeutics Inc down on Monday (HLS)
HLS Therapeutics Names Craig Millian CEO - Quick Facts
HLS Therapeutics Announces CEO Transition
Closing Bell: Hls Therapeutics Inc up on Friday (HLS)
Closing Bell: Hls Therapeutics Inc up on Wednesday (HLS)
Closing Bell: Hls Therapeutics Inc down on Tuesday (HLS)
Closing Bell: Hls Therapeutics Inc up on Monday (HLS)
Closing Bell: Hls Therapeutics Inc up on Tuesday (HLS)
See More Headlines

HLS Price History

HLS Company Calendar

Ex-Dividend for 3/15 Dividend
1/30/2023
Dividend Payable
3/15/2023
Last Earnings
3/16/2023
Ex-Dividend for 6/15 Dividend
4/27/2023
Today
6/05/2023
Dividend Payable
6/15/2023
Next Earnings (Estimated)
8/10/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
92
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$19.80
High Stock Price Forecast
C$26.50
Low Stock Price Forecast
C$15.00
Forecasted Upside/Downside
+464.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
C$-25,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$61.67 million
Cash Flow
C$0.28 per share
Book Value
C$3.67 per share

Miscellaneous

Free Float
N/A
Market Cap
C$139.11 million
Optionable
Not Optionable
Beta
0.88

Key Executives

  • Mr. Gregory David Gubitz B.A. (Age 66)
    L.L.B., LL.B, Co-Founder & Chairman
    Comp: $289.94k
  • Mr. Gilbert Godin (Age 64)
    Co-Founder, CEO & Director
    Comp: $857.38k
  • Mr. Tim Hendrickson M.B.A. (Age 51)
    Chief Financial Officer
    Comp: $402.33k
  • Mr. Sanjiv Sharma (Age 67)
    Chief Commercial Officer
    Comp: $486.69k
  • Mr. Ryan C. Lennox B.A. (Age 42)
    J.D., Sr. VP of Legal, HR & Compliance and Corp. Sec.
  • David Spence (Age 55)
    Corp. Controller













HLS Stock - Frequently Asked Questions

Should I buy or sell HLS Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HLS shares.
View HLS analyst ratings
or view top-rated stocks.

What is HLS Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued 1 year price objectives for HLS Therapeutics' stock. Their HLS share price forecasts range from C$15.00 to C$26.50. On average, they anticipate the company's share price to reach C$19.80 in the next year. This suggests a possible upside of 360.5% from the stock's current price.
View analysts price targets for HLS
or view top-rated stocks among Wall Street analysts.

How have HLS shares performed in 2023?

HLS Therapeutics' stock was trading at C$9.83 at the beginning of the year. Since then, HLS shares have decreased by 56.3% and is now trading at C$4.30.
View the best growth stocks for 2023 here
.

When is HLS Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our HLS earnings forecast
.

How were HLS Therapeutics' earnings last quarter?

HLS Therapeutics Inc. (TSE:HLS) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.18. The business had revenue of $21.28 million for the quarter, compared to analyst estimates of $22.56 million. HLS Therapeutics had a negative net margin of 41.79% and a negative trailing twelve-month return on equity of 18.55%.

How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics?

HLS Therapeutics announced a quarterly dividend on Thursday, April 27th. Stockholders of record on Thursday, June 15th will be paid a dividend of 0.05 per share on Thursday, June 15th. This represents a $0.20 annualized dividend and a dividend yield of 4.65%. The ex-dividend date is Thursday, April 27th.
Read our dividend analysis for HLS
.

Is HLS Therapeutics a good dividend stock?

HLS Therapeutics (TSE:HLS) pays an annual dividend of C$0.20 per share and currently has a dividend yield of 4.61%. HLS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for HLS.

What other stocks do shareholders of HLS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO) and Bank of Nova Scotia (BNS).

What is HLS Therapeutics' stock symbol?

HLS Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HLS."

How do I buy shares of HLS Therapeutics?

Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is HLS Therapeutics' stock price today?

One share of HLS stock can currently be purchased for approximately C$4.30.

How much money does HLS Therapeutics make?

HLS Therapeutics (TSE:HLS) has a market capitalization of C$139.11 million and generates C$61.67 million in revenue each year. The company earns C$-25,770,000.00 in net income (profit) each year or C($1.12) on an earnings per share basis.

How can I contact HLS Therapeutics?

The official website for the company is www.hlstherapeutics.com. The company can be reached via phone at 647-495-9000.

This page (TSE:HLS) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -